Our Goal:
Treat the Untreatable
Humacyte is pioneering the development and manufacture of off-the-shelf, universally implantable bioengineered human tissues. The Humacyte Human Acellular Vessel (HAV) is a regenerative vascular conduit currently in various stages of clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. We believe our platform technology also has the potential to create solutions for complex organ disease, including bioengineered replacement tissues and organs for coronary artery bypass grafts, pediatric heart surgery, and the treatment of Type 1 diabetes.
Innovation at
Commercial Scale
Humacyte is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at a commercial scale with the goal of improving the lives of patients and transforming the practice of medicine. Humacyte develops and manufactures acellular tissues to address life- and limb-threatening vascular conditions while focusing on potential future applications for complex organ disease. Located in Durham, N.C., Humacyte announced the intent to go public via a SPAC in February 2021. The company was founded in 2004 by Laura Niklason, MD, Ph.D., a world leader in tissue engineering and the Chief Executive Officer of Humacyte, along with Drs. Juliana Blum and Shannon Dahl.
